This deposit contains the data, code, and analysis to recreate the results in the manuscript - Tuulikki Suomela, Liang Zhang, Julio Vera, Heiko Bruns, Xin Lai. A Practical Guideline for MicroRNA Sequencing Data Analysis in Chronic Lymphocytic Leukemia. Methods Mol. Biol., 2883, 403–426. https://doi.org/10.1007/978-1-0716-4290-0_18.

The pipeline allows users to perform end-to-end analysis of bulk miRNA sequencing data, including quality control of FastQ files, mapping of read counts to miRNA genes using miRBase or Reference genome, quantification of miRNA read counts, differential gene expression analysis using DEseq2, gene set enrichment analysis using curated cancer hallmark gene sets, and identification of miRNA targets.

If you have used the code for your research, please cite the original publication. Thank you very much.

Cancer is the second most common cause of mortality worldwide, accounting for almost 10 million deaths in 2020. These deaths were partly due to delayed diagnosis that led to deferred treatment. Therefore, new diagnostic methods are necessary to enhance the accuracy of noninvasive cancer detection. The present study developed a microRNA (miRNA)-based serum diagnostic marker for detecting a wide range of cancers. The study involved 61,019 serum samples from 19 different cancer types. A miRNA prediction model was established through bioinformatics analysis of serum samples from various cancer pathologies and qRT-PCR results from studies in PubMed aligned to the analysis criteria. R software v.4.1.1 with the limma data analysis package was used for single gene expression series data series, and batchNormalize and robustRankAggreg were used to predict the changes in miRNA expression in multiple datasets. GO and KEGG analyses showed that these miRNAs play a role in cancer-related biological signaling pathways. Finally, the diagnostic capability of these miRNA biomarkers was assessed using area under the curve analysis. The study predicted that 7 miRNAs were upregulated and 10 miRNAs were downregulated in 19 different types of cancer. Some miRNAs showed significant differential expression in a specific cancer type. Additionally, downstream genes regulated by miRNAs focused on many cancer-related molecular signaling pathways. In this review, we summarize the current understanding of miRNAs in various cancers, with a particular focus on their potential as future noninvasive diagnostic biomarkers. The emphasis is on their capacity for achieving high accuracy and cost savings compared to conventional biomarkers.

The global microRNA sequencing (miRNA-Seq) market is experiencing robust growth, driven by the increasing understanding of microRNAs' crucial roles in various biological processes and disease development. This has fueled significant demand for miRNA-Seq technologies across diverse research and clinical applications, including cancer diagnostics, drug discovery, and personalized medicine. The market's expansion is further propelled by technological advancements, leading to more efficient, cost-effective, and higher-throughput miRNA-Seq platforms. These advancements include improvements in library preparation, sequencing technologies (like next-generation sequencing – NGS), and bioinformatics analysis tools, enabling researchers to analyze complex miRNA profiles with greater accuracy and speed. The market is segmented by technology (e.g., NGS, microarrays), application (e.g., oncology, cardiology, neurology), and end-user (e.g., academic research, pharmaceutical companies). Competition is intense, with major players like Illumina, Thermo Fisher Scientific, and Qiagen leading the market, constantly innovating to maintain their market share. Despite the substantial growth, the market faces certain restraints. High costs associated with miRNA-Seq experiments, including sequencing and data analysis, remain a significant barrier, especially for smaller research institutions and laboratories in developing countries. Furthermore, the complexity of bioinformatics analysis and the need for specialized expertise can limit broader adoption. Nevertheless, ongoing research and development efforts aimed at reducing costs and streamlining the analytical workflow are likely to mitigate these limitations. The forecast period (2025-2033) indicates a sustained high growth trajectory due to the expanding applications of miRNA-Seq in precision medicine initiatives and the increasing number of clinical trials employing miRNA biomarkers for diagnostics and prognostics. The strategic partnerships between technology providers and research institutions are also expected to drive market growth throughout the forecast period. We estimate a compound annual growth rate (CAGR) of approximately 15% for the miRNA-Seq market from 2025 to 2033, assuming a 2025 market size of $1.5 Billion, based on industry reports and growth trends observed in related genomics markets.

The microRNA (miRNA) sequencing and assay market is experiencing robust growth, driven by the increasing understanding of miRNA's role in various diseases and its potential as a diagnostic and therapeutic target. The market's Compound Annual Growth Rate (CAGR) of 10.90% from 2019-2024 indicates a significant expansion, projected to continue into the forecast period (2025-2033). This growth is fueled by advancements in sequencing technologies, such as next-generation sequencing (NGS), enabling high-throughput and cost-effective miRNA profiling. The development of sophisticated library preparation kits and readily available sequencing consumables further simplifies the workflow, making miRNA analysis accessible to a broader range of researchers and clinicians. Key market segments include sequencing consumables (probes, reagents, etc.), library preparation kits optimized for miRNA, and various sequencing technologies like Sequencing by Synthesis, Ion Semiconductor, SOLiD, and Nanopore sequencing. The clinical laboratory and life science organization segments are the primary end-users, driving demand for accurate and efficient miRNA analysis for both research and diagnostic applications. While the market faces restraints such as the high cost of sequencing and data analysis, the increasing availability of affordable sequencing platforms and bioinformatics tools is mitigating this challenge. Geographic regions like North America and Europe currently hold a significant market share due to established research infrastructure and advanced healthcare systems, but the Asia-Pacific region is expected to exhibit substantial growth in the coming years due to increasing research activities and rising healthcare expenditure. The competitive landscape is characterized by a mix of established players like Illumina, Thermo Fisher Scientific, and Qiagen, alongside specialized companies focusing on miRNA-specific solutions such as Lexogen and Norgen Biotek. Strategic partnerships and technological advancements are shaping the market dynamics, with companies constantly striving to enhance the sensitivity, specificity, and cost-effectiveness of miRNA sequencing and assay platforms. The future growth trajectory will be influenced by factors like the development of novel miRNA biomarkers, the integration of artificial intelligence for data analysis, and the increasing adoption of personalized medicine approaches utilizing miRNA profiling. The expansion of point-of-care diagnostics and the increasing demand for liquid biopsies for early cancer detection are also significant growth drivers. The market is projected to reach substantial value by 2033, driven by continued technological advancements and increasing applications across various fields. Recent developments include: April 2022: HTC Molecular Diagnostics Inc. unveiled new features of its proprietary HTG EdgeSeq technology. The company has improved its technology, and now its new sample preparation harmonization enables miRNA and mRNA profiling without the need for additional samples., January 2022: Allogene Therapeutics announced a collaboration with Antion Biosciences to advance multiplex gene silencing for the development of next-generation allogeneic CAR T products. As part of the collaboration, Antion's miRNA technology (miCAR) will be used as an additional tool to enhance the efficacy and safety of allogeneic CAR T therapies.. Key drivers for this market are: MiRNA Sequencing and Assay Sequencing Supremacy Over Other Methods, Increased Research in the Field of Genomics; Reduced Sequencing Costs. Potential restraints include: Paucity of Expert and Need for Computing Infrastructure. Notable trends are: Library Preparation Kits are Expected to Hold the Largest Market Share in the miRNA Sequencing and Assay Market.

Snapshot img

Microrna (Mirna) Market Size 2024-2028

The microrna (mirna) market size is forecast to increase by USD 3.19 billion at a CAGR of 23.31% between 2023 and 2028.

The miRNA market is experiencing significant growth due to the increasing prevalence of neurological disorders, which is driving the demand for miRNA-based therapeutics. Furthermore, the market is witnessing an upward trend In the number of partnerships and collaborations among market participants, leading to advancements in miRNA research and technology. However, the high heterogeneity of methodologies associated with miRNA isolation, identification, and quantification poses a challenge to the market's standardization and commercialization. These trends and challenges are shaping the future of the miRNA market and are expected to influence its growth trajectory In the coming years.

What will be the Size of the Microrna (Mirna) Market During the Forecast Period?

Request Free SampleThe miRNA market encompasses a diverse range of applications, primarily focused on the diagnosis and treatment of various chronic disorders, including cancer, cardiovascular diseases, and neurological disorders. This market is driven by the increasing adoption of genomic technologies in precision medicine, which enables the development of noninvasive biomarkers for early disease detection and monitoring. MiRNAs, small non-coding RNAs, play a crucial role in gene regulation and have emerged as promising diagnostic tools for several diseases. In the field of oncology, miRNAs have gained significant attention due to their role as tumor suppressors and oncogenes. MiRNAs are also being explored for vaccine development and disease diagnostics.The market for miRNA-based instruments, kits, and reagents is expanding, with a focus on isolation and purification techniques for high-quality samples. Healthcare facilities are increasingly adopting molecular diagnostics, including real-time PCR, next-generation sequencing, microarrays, and liquid biopsies, to leverage miRNAs as biomarkers for disease diagnosis and monitoring. Clinical studies continue to explore the potential of miRNAs in chronic disorders, with a focus on standardized protocols for non-invasive methods.

How is this Microrna (Mirna) Industry segmented and which is the largest segment?

The microrna (mirna) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. TypeConsumablesInstrumentsEnd-userAcademic and government research institutesBiotechnology and pharmaceutical companiesCROs and clinical diagnostic centersGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Type Insights

The consumables segment is estimated to witness significant growth during the forecast period.

The miRNA market encompasses a range of applications, including cancer, cardiovascular diseases, neurological disorders, and infectious diseases. This market is driven by the increasing demand for genomic technologies, precision medicine, and noninvasive biomarkers. MiRNAs play a crucial role in gene regulation, disease diagnostics, and therapeutic applications. They are used for target prediction, vaccine development, and immunological status assessment. The market includes research institutions and academic institutes, which contribute significantly to the advancement of miRNA-based therapeutics and diagnostics. Consumables, such as whole blood, serum, and plasma, are essential for miRNA isolation and purification, and their repeated usage fuels market growth. End-users, including healthcare facilities and clinical trials, require a variety of reagents and kits for miRNA detection and analysis.The market also includes instruments, diagnostic kits, real-time PCR, next-generation sequencing, microarrays, and liquid biopsies. Standardized protocols and high-quality samples are crucial for accurate and reliable miRNA analysis. The market is poised for growth due to the potential of miRNAs in early detection and treatment of chronic disorders, tumor suppressor miRNAs, and therapeutic compounds.

Get a glance at the Microrna (Mirna) Industry report of share of various segments Request Free Sample

The Consumables segment was valued at USD 484.70 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 43% to the growth of the global market during the forecast period.

Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The miRNA market in North America is currently the largest globally, driven by substantial investmen

We investigated the miRNAome in human melanocyte and melanoma cell lines using high-throughput RNA sequencing. We identified a group of dysregulated miRNAs by comparing the miRNA expression profiles among melanoma cell lines. Target genes of these miRNAs participate in functions associated with the cell cycle and apoptosis. Gene networks were built to investigate the interactions of genes during melanoma progression. We identified that the key genes that regulate melanoma cell proliferation were regulated by miRNAs. Our findings provide further knowledge regarding the mechanisms of melanoma development. Overall design: miRNA profiles of melanocyte (HEMn-LP), low metastatic melanoma (A375) and high metastatic melanoma (A2058) cell line were generated using Illumina GA

This dataset contains the results of 2 related analyses, described in "Bayesian network analysis of plasma microRNA sequencing data in patients with venous thrombosis" (European Heart Journal Supplements, OUP). Link to the article: https://www.hal.inserm.fr/inserm-02310241

1) In the directory "miRNAs_MARTHA_GWAS" : GWAS summary statistics for 162 circulating miRNAs in 344 VTE patients from the MARTHA cohort.

Header for each summary file:

Trait: miRNA id
chr: Chromosome
pos.hg19: Position of the variant in hg19/GRCh37 coordinates
SNP: rsid
A1: Reference allele on the forward strand
A2: Alternate allele on the forward strand
freq_A1: Frequency of reference allele
rsqr: Imputation quality defined by MACH
beta_A1: Estimated effect size (beta regression coefficient) of reference allele
se_A1: Estimated standard error of beta
p: p-value (significance of estimated beta)
z.score: Z-score

2) In the directory "meta_analysis": Random effect meta-analysis combining the results of our GWAS on the MARTHA cohort, and the results from a similar analysis conducted by Nikpay et al. (doi: 10.1093/cvr/cvz030). Summary statistics of 142 microRNAs, common to both datasets, were processed (and combine 1054 samples).

Header for each summary file:

chr: Chromosome
pos.hg19: Position of the variant in hg19/GRCh37 coordinates
SNP: rsid
A1: Reference allele on the forward strand
A2: Alternate allele on the forward strand
N: Sample size
Q: Cochran's heterogeneity statistic
Q.p: p-value of Cochran's Q
beta_A1: Estimated effect size (beta regression coefficient) of reference allele
se_A1: Estimated standard error of beta
p: p-value (significance of estimated beta)

MicroRNA (miRNA) Market Outlook

In 2023, the global market size for MicroRNA (miRNA) is estimated to be around USD 1.5 billion, with a projected CAGR of 13% from 2024 to 2032. By 2032, this market is expected to reach a valuation of approximately USD 4.7 billion. The growth of the miRNA market can largely be attributed to increasing research activities focused on understanding gene expression and the role of miRNA in various diseases, amongst other factors.

One of the primary growth factors driving the miRNA market is the surge in research and development activities in the field of molecular biology and genetic engineering. Universities, research institutions, and biopharmaceutical companies are investing heavily in miRNA research to better understand its regulatory mechanisms and therapeutic potential. This increased focus is driven by the recognition of miRNAs as critical regulators of gene expression, which play significant roles in a variety of biological processes and diseases. Consequently, the demand for miRNA products such as inhibitors, mimics, and probes is escalating, further propelling market growth.

Another crucial driver is the growing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders, which has intensified the need for novel diagnostic and therapeutic solutions. miRNAs have shown promise as biomarkers for early disease detection and as targets for innovative therapeutic approaches. For instance, miRNAs can help in identifying cancer subtypes, leading to more personalized and effective treatment strategies. The expanding applications of miRNA in clinical settings are thus contributing to the market's robust growth trajectory.

Technological advancements in miRNA research tools and methodologies are also playing a pivotal role in market expansion. Innovations such as next-generation sequencing (NGS), digital PCR, and advanced bioinformatics tools have significantly improved the accuracy and efficiency of miRNA profiling and analysis. These technological advancements facilitate better understanding and manipulation of miRNAs, thereby accelerating their integration into clinical and diagnostic applications. Enhanced research capabilities are expected to continue driving market growth in the coming years.

The growing importance of miRNA Tools and Services is evident as they provide essential support for researchers and clinicians working in the field of miRNA. These tools and services encompass a wide range of offerings, including software for miRNA target prediction, databases for miRNA expression profiles, and platforms for miRNA data analysis. The availability of these tools facilitates the efficient analysis and interpretation of miRNA data, enabling researchers to uncover novel insights into miRNA function and regulation. As the demand for miRNA-based diagnostics and therapeutics continues to rise, the role of miRNA Tools and Services becomes increasingly critical in advancing research and clinical applications.

Regionally, North America is expected to dominate the miRNA market due to its well-established healthcare infrastructure, significant investment in research and development, and the presence of major biopharmaceutical companies. Europe is anticipated to follow, driven by similar factors, including strong academic research communities and supportive regulatory frameworks. The Asia Pacific region is poised for substantial growth as well, owing to increasing healthcare expenditure, rising awareness about miRNA technologies, and expanding biotech industries in countries like China and India. Overall, regional disparities in market growth are shaped by variations in research funding, healthcare infrastructure, and regulatory landscapes.

Product Type Analysis

Inhibitors Analysis

Inhibitors represent a significant segment within the miRNA market, primarily used to silence specific miRNAs. These molecules are designed to bind to their target miRNA and inhibit its function, offering a valuable tool for research and therapeutic applications. The growing need to understand miRNA function and the development of miRNA-based therapeutics are key drivers for this segment. Inhibitors are extensively used in various research settings to study the role of specific miRNAs in disease pathways, which has fueled their demand.

Additionally, the development of miRNA inhibitors has significant therapeutic im

CoV, CoV_imp_missF, CoV_imp_VIM, CoV_imp_max_one, and CoV_imp_na_35 –coefficient of variation for particular RNA in a raw dataset, in the missF imputed dataset, in the VIM imputed dataset, in max_one imputed dataset and na_35 imputed dataset, respectively.

The microRNA (miRNA) sequencing and assay market is experiencing robust growth, driven by advancements in sequencing technologies and the increasing understanding of miRNA's role in various diseases. The market, valued at $445.2 million in 2025, is projected to exhibit significant expansion over the forecast period (2025-2033). While the provided CAGR is missing, considering the rapid advancements in genomics and the growing demand for personalized medicine, a conservative estimate of the Compound Annual Growth Rate (CAGR) would be around 15% – 20%. This growth is fueled by several key factors: the rising prevalence of cancer and other diseases where miRNA plays a crucial role in diagnosis and prognosis; the increasing adoption of next-generation sequencing (NGS) technologies offering higher throughput and lower costs; and the growing use of miRNA assays in drug discovery and development. The market is segmented by sequencing technology (Sequencing by Synthesis, Sequencing by Nanopore, Ion Semiconductor Sequencing) and application (Research Institute, Academia, CRO). Illumina, Thermo Fisher Scientific, QIAGEN, Takara Bio, and NEB are key players dominating the market landscape, continuously innovating to improve the efficiency and affordability of miRNA sequencing and assay technologies. The geographical distribution of the market reveals significant regional variations. North America currently holds a substantial market share due to the presence of major research institutions, well-established healthcare infrastructure, and early adoption of advanced technologies. However, the Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by increasing healthcare expenditure, rising prevalence of chronic diseases, and a growing number of genomics research initiatives. Europe and other regions will also contribute significantly, though at possibly slower rates than the Asia-Pacific region. Further market penetration will depend on regulatory approvals, advancements in data analysis capabilities, and the development of cost-effective solutions to improve accessibility in emerging markets.

This is the Raw Data Files of the sequencing data. And the original datas about the Differentially_Expressed_miRNAs, GO Analysis Results (miRNA Targets),miRNA_Targets_Prediction,novel_miRNAs_predicted_by_miRDeep2, and Pathway Analysis Results (miRNA Targets).

The wild grass Brachypodium distachyon has emerged as a model system for temperate grasses and biofuel plants. However, the global analysis of miRNAs, molecules known to be key for eukaryotic gene regulation, has been limited in B. distachyon to studies examining a few samples or that rely on computational predictions. Similarly an in-depth global analysis of miRNA-mediated target cleavage using Parallel Analysis of RNA Ends (PARE) data is lacking in B. distachyon. B. distachyon small RNAs were cloned and deeply sequenced from 17 libraries that represent different tissues and stresses. Using a computational pipeline, we identified 116 miRNAs including not only conserved miRNAs that have not been reported in B. distachyon, but also non-conserved miRNAs that were not found in other plants. To investigate miRNA-mediated cleavage function, four PARE libraries were constructed from key tissues and sequenced to a total depth of approximately 70 million sequences. The roughly 5 million distinct genome-matched sequences that resulted represent an extensive dataset to analyze small RNA-guided cleavage events. Analysis of the PARE and miRNA data provided experimental evidence for miRNA-mediated cleavage of 264 sites in predicted miRNA targets. In addition, PARE analysis revealed that differentially expressed miRNAs in the same family guide specific target RNA cleavage in a correspondingly tissue-preferential manner. B. distachyon miRNAs and target RNAs were experimentally identified and analyzed. Knowledge gained from this study should provide insights into the roles of miRNAs and the regulation of their targets in B. distachyon and related plants. Examination of various tissues and stresses in Brachypodium by high throughput sequencing for small RNA profiling and PARE (Parallel Analysis of RNA Ends)

In developed countries, cardiovascular diseases are currently the first cause of death. Cardiospheres (CSs) and cardiosphere-derived cells (CDCs) have been found to have the ability to regenerate the myocardium after myocardial infarction (MI). In recent years, much effort has been made to gain insight into the human heart repair mechanisms, in which miRNAs have been shown to play an important role. In this regard, to elucidate the involvement of miRNAs, we evaluated the miRNA expression profile across human heart biopsy, CSs and CDCs using microarray and next-generation sequencing (NGS) technologies. We identified several miRNAs more represented in the progenitors, where some of them can be responsible for the proliferation or the maintenance of an undifferentiated state, while others have been found to be downregulated in the undifferentiated progenitors compared with the biopsies. Moreover, we also found a correlation between downregulated miRNAs in CSs/CDCs and patient age (eg miR-490) and an inverse correlation among miRNAs upregulated in CSs/CDCs (eg miR-31).

miRNA sequencing data during 2-, 6-, and 12- month-old Small Tail Han Sheep ovaries,

This study presents the isolation of exosomes and RNA from 20 samples of white-tailed deer serum using a commercially available kit, incorporating optimizations for RNA yield through two elutions and replicate pooling. The RNA yield from each method is reported, with six samples processed using three techniques. Seven samples underwent RNA sequencing, where total RNA was prepared for miRNA analysis using the NEBNext library preparation protocol. Adaptors were ligated to the sRNA ends, and cDNA libraries were generated through PCR enrichment. Sequencing was performed on the Illumina NovaSeq 6000 platform with 50 bp single-end reads. Data analysis involved filtering raw reads, mapping sequences against the white-tailed deer reference genome, and aligning mapped sRNA to miRBase22 for known miRNA structures. Novel miRNA predictions were made using miREvo and mirdeep2. Six samples yielded at least 1 million reads, with a Pearson’s correlation coefficient (⍴) greater than 0.7, while one sample was excluded due to insufficient sequencing depth.

The global MicroRNA (miRNA) market size was valued at USD 6.7 billion in 2025 and is projected to reach USD 24.9 billion by 2033, growing at a CAGR of 17.2% during the forecast period (2025-2033). The market growth is attributed to the rising prevalence of chronic diseases, increasing demand for personalized medicine, and continuous advancements in miRNA research and technology. The major factors driving the growth of the miRNA market include the increasing demand for miRNA-based diagnostics and therapeutics, the increasing adoption of miRNA profiling in disease research and drug development, and the growing number of collaborations between pharmaceutical companies and academic institutions. However, the high cost of miRNA-based products and the lack of standardized regulations for miRNA testing are restraining the market growth. North America currently dominates the miRNA market, followed by Europe and Asia-Pacific. The Asia-Pacific region is expected to grow rapidly during the forecast period due to the increasing investment in healthcare infrastructure and the growing awareness of miRNA-based technologies. MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a critical role in regulating gene expression. They are involved in various biological processes, including cell growth, differentiation, and apoptosis. As a result, miRNAs have become increasingly important in the field of biomedical research.

This dataset is about the differentially expressed exosomal microRNA between MCPyV-negative and -positive MCC cell lines. Abstract: MicroRNAs (miRNAs) are small non-coding RNAs responsible for post-transcriptional regulation of gene expression through interaction with messenger RNAs (mRNAs). In the past few years, evidence of the presence of cellular miRNAs in extracellular human body fluids such as serum, plasma, saliva, and urine has accumulated. Also, miRNAs have found in membrane-bound vesicles such as exosomes. They are involved in critical biological processes and dysregulated in a variety of diseases, including cancer and infections. Although little known about the role of exosomal miRNAs, it has demonstrated that miRNAs secreted by virus-infected cells transferred to and act in uninfected recipient cells, thereby contributing to spreading the pathogenic properties of the virus. Merkel cell carcinoma (MCC) is skin cancer of neuroendocrine origin. The significant risk factors are ultraviolet light exposure and the presence of integrated Merkel cell polyomavirus (MCPyV) genome. In this work, we sequenced exosomal miRNAs of MCPyV-negative (MCC13 and MCC26) and –positive MCC (MKL1 and MKL2) cell lines. In total, 519 exosomal miRNA were identified as a differentially expressed between the virus-negative and virus-positive cell lines and selected eight exosomal miRNA validated on exosomal serum/plasma healthy donors and MCC patients by qRT-PCR. miR-222-3p target genes predicted using the ExoCarta, TargetScan, and miRTarBase databases to understand the exosomal miR-222-3p influence in health and disease. The result showed the miR-222-3p is present in exosomes from Merkel cell carcinoma cell culture, serum of healthy donors and plasma of MCC patients. The sequencing result indicated that miR-222-3p is more abundant in exosomes generated by virus-negative MCC cells than in exosomes secreted by virus-positive MCC cell lines. qRT-PCR validation confirmed this finding — however, the miR-222-3p presence at a higher level in exosomes in healthy condition than in pathophysiological state. The enrichment analysis showed 11 of predicted 20 common miR-222-3p targets expressed in leukocytes and 6 of them identified as differentially expressed proteins in MCC cell lines. The role of miR-222-3p as the messenger in the cell-to-cell communication in the cancer environment and circulation discussed.

data was from HepG2 cells treated with nano-silver particles using silver nitrate as negative controls. Differentially expressed messenger RNA and microRNA were obtained by RNA sequencing and data analysis. Differentially expressed RNA and microRNA lists were than uploaded to Ingenuity Pathway Analysis to find the pathways altered by the differentially expressed genes. This dataset is associated with the following publication: Thai, S., C. Jones, B. Robinette, H. Ren, B. Vallanat, A. Fisher, and K. Kitchin. Effects of Silver Nanoparticles and Silver Nitrate on mRNA and microRNA Expression in Human Hepatocellular Carcinoma Cells (HepG2). Journal of Nanoscience and Nanotechnology. American Scientific Publishers, VALENCIA, CA, USA, 21(11): 5414-5428, (2021).

The microRNA (miRNA) sequencing and assay market is experiencing robust growth, driven by the increasing understanding of miRNA's role in various diseases and its potential as a diagnostic and therapeutic target. The market's expansion is fueled by advancements in sequencing technologies, particularly next-generation sequencing (NGS), which offer higher throughput, lower costs, and improved accuracy compared to traditional methods. The rising prevalence of chronic diseases like cancer, cardiovascular diseases, and neurological disorders, coupled with the increasing demand for personalized medicine, is significantly boosting the adoption of miRNA sequencing and assays. Furthermore, the development of sophisticated bioinformatics tools for analyzing miRNA sequencing data enhances the market's appeal. While the high cost of sequencing and the complexity of data analysis can act as restraints, the market is expected to overcome these challenges through technological innovations and the emergence of cost-effective solutions. The clinical laboratory segment holds a significant share due to the rising demand for accurate and timely diagnostics. Major players in this field, including Illumina, Thermo Fisher Scientific, and Qiagen, are actively engaged in developing advanced miRNA sequencing platforms and assays, fostering innovation and driving competition within the market. The market is segmented by product (sequencing consumables, library preparation kits), technology (sequencing by synthesis, ion semiconductor, SOLiD, nanopore sequencing), and end-user (clinical laboratories, life science organizations). The projected Compound Annual Growth Rate (CAGR) of 5.60% indicates a steadily expanding market over the forecast period (2025-2033). Regional variations exist, with North America and Europe currently dominating the market due to advanced healthcare infrastructure and substantial research funding. However, the Asia-Pacific region is anticipated to witness significant growth in the coming years, driven by rising healthcare expenditure and increasing awareness about miRNA's diagnostic potential. The continuous development of novel miRNA-based diagnostic tests and therapeutic strategies will further fuel the market's expansion. Competitive landscape analysis reveals a mix of large multinational corporations and specialized biotechnology firms. These companies are focusing on strategic partnerships, acquisitions, and research and development activities to gain a competitive edge and expand their market share. The focus on improving assay sensitivity and specificity, along with efforts to reduce costs, will play a key role in shaping the future of the miRNA sequencing and assay market. Recent developments include: November 2023: Fluent BioSciences announced a partnership with Singular Genomics, a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians. Together, they unveiled the compatibility of PIPseq Single Cell RNA Kits with sequencing on the Singular Genomics G4 Sequencing Platform.May 2023: Twist Bioscience Corporation announced the launch of a portfolio of RNA sequencing tools, which included the Twist RNA Exome, Twist RNA Library Prep Kit, and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing.. Key drivers for this market are: Supremacy of miRNA Sequencing and Assay Sequencing Over Other Methods, Increased Research in the Field of Genomics; Reduced Sequencing Costs. Potential restraints include: Supremacy of miRNA Sequencing and Assay Sequencing Over Other Methods, Increased Research in the Field of Genomics; Reduced Sequencing Costs. Notable trends are: Library Preparation Kits Projected to Hold the Largest Market Share.

Comparison of stability rankings for selected miRNAs in different subsets of two external datasets: GSE81873 and GSE43867.